
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc., a commercial-stage medical technology company, demonstrated growth in its EsoGuard testing, processing 2,841 tests in Q3, reflecting an increase from previous quarters, indicating a strengthening demand for its diagnostics products. The company's current valuation is seen as attractive, balancing the high risks associated with its operations against substantial upside opportunities, particularly as its product lines continue to advance toward broader commercialization. Additionally, projections suggest significant growth potential for the company’s offerings in the upcoming years, particularly for its medical devices and digital health segments.
Bears say
PAVmed Inc has reported a pro forma net loss of $0.8 million, equating to an earnings per share (EPS) of $(0.05), which is significantly better than prior estimates but still indicates ongoing financial challenges. The company experienced a decline in the number of EsoGuard tests processed, which decreased to 2,756 in Q2 from 3,034 in Q1, reflecting a concerning downward trend in service utilization. Additionally, PAVmed faces numerous operational and market risks, including balance sheet and liquidity pressures, regulatory hurdles, and competition, all of which complicate its path to growth and commercialization.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares